NYSE:USPH - U.S. Physical Therapy Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $118.01 +2.54 (+2.20 %) (As of 05/20/2019 04:00 PM ET)Previous Close$115.47Today's Range$114.4650 - $118.645052-Week Range$93.00 - $129.65Volume79,618 shsAverage Volume89,024 shsMarket Capitalization$1.51 billionP/E Ratio44.53Dividend Yield0.94%Beta1.15 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company provides industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors As of March 14, 2019, it operated 592 outpatient physical therapy clinics in 42 states; and managed 28 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The company was founded in 1990 and is based in Houston, Texas. Receive USPH News and Ratings via Email Sign-up to receive the latest news and ratings for USPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Health services Sub-IndustryHealth Care Facilities SectorMedical Current SymbolNYSE:USPH Previous Symbol CUSIP90337L10 CIK885978 Webwww.usph.com Phone713-297-7000Debt Debt-to-Equity Ratio0.39 Current Ratio1.18 Quick Ratio1.18Price-To-Earnings Trailing P/E Ratio44.53 Forward P/E Ratio40.41 P/E Growth3.52 Sales & Book Value Annual Sales$453.91 million Price / Sales3.32 Cash Flow$3.4863 per share Price / Cash Flow33.85 Book Value$17.33 per share Price / Book6.81Profitability EPS (Most Recent Fiscal Year)$2.65 Net Income$34.87 million Net Margins5.34% Return on Equity19.09% Return on Assets8.86%Miscellaneous Employees4,600 Outstanding Shares12,761,000Market Cap$1.51 billion Next Earnings Date8/1/2019 (Estimated) OptionableOptionable U.S. Physical Therapy (NYSE:USPH) Frequently Asked Questions What is U.S. Physical Therapy's stock symbol? U.S. Physical Therapy trades on the New York Stock Exchange (NYSE) under the ticker symbol "USPH." How often does U.S. Physical Therapy pay dividends? What is the dividend yield for U.S. Physical Therapy? U.S. Physical Therapy declared a quarterly dividend on Friday, May 3rd. Shareholders of record on Friday, May 17th will be given a dividend of $0.27 per share on Friday, June 14th. This represents a $1.08 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Thursday, May 16th. View U.S. Physical Therapy's Dividend History. How were U.S. Physical Therapy's earnings last quarter? U.S. Physical Therapy, Inc. (NYSE:USPH) released its quarterly earnings results on Thursday, May, 2nd. The company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.04. The company had revenue of $116.23 million for the quarter, compared to analysts' expectations of $114.12 million. U.S. Physical Therapy had a return on equity of 19.09% and a net margin of 5.34%. The firm's quarterly revenue was up 7.3% compared to the same quarter last year. View U.S. Physical Therapy's Earnings History. When is U.S. Physical Therapy's next earnings date? U.S. Physical Therapy is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for U.S. Physical Therapy. What guidance has U.S. Physical Therapy issued on next quarter's earnings? U.S. Physical Therapy updated its FY 2019 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of $2.76-2.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.80. The company issued revenue guidance of $35.1-36.4 million, compared to the consensus revenue estimate of $480.84 million. What price target have analysts set for USPH? 4 brokers have issued twelve-month price targets for U.S. Physical Therapy's shares. Their predictions range from $105.00 to $107.00. On average, they expect U.S. Physical Therapy's stock price to reach $106.2033 in the next twelve months. This suggests that the stock has a possible downside of 10.0%. View Analyst Price Targets for U.S. Physical Therapy. What is the consensus analysts' recommendation for U.S. Physical Therapy? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for U.S. Physical Therapy in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for U.S. Physical Therapy. What are Wall Street analysts saying about U.S. Physical Therapy stock? Here are some recent quotes from research analysts about U.S. Physical Therapy stock: 1. Barrington Research analysts commented, "We think this guidance is likely conservative and would not be surprised to see the adjusted EPS guidance increase as early as next quarter. Our current adjusted EPS expectation is $2.92." (5/3/2019) 2. According to Zacks Investment Research, "U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh's clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company's growth, are structured like the de novo partnerships, with significant ownership retained by founders. " (4/26/2019) Has U.S. Physical Therapy been receiving favorable news coverage? Media headlines about USPH stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. U.S. Physical Therapy earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of U.S. Physical Therapy's key competitors? Some companies that are related to U.S. Physical Therapy include Encompass Health (EHC), Exelixis (EXEL), GALAPAGOS NV/S (GLPG), Amarin (AMRN), PRA Health Sciences (PRAH), Medidata Solutions (MDSO), Nektar Therapeutics (NKTR), Hikma Pharmaceuticals (HKMPF), athenahealth (ATHN), Chemed (CHE), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND), Haemonetics (HAE), NMC Health (NMC) and Penumbra (PEN). What other stocks do shareholders of U.S. Physical Therapy own? Based on aggregate information from My MarketBeat watchlists, some companies that other U.S. Physical Therapy investors own include Allergan (AGN), Qorvo (QRVO), Yandex (YNDX), Baxter International (BAX), Cleveland-Cliffs (CLF), Booking (BKNG), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Illumina (ILMN) and Prospect Capital (PSEC). Who are U.S. Physical Therapy's key executives? U.S. Physical Therapy's management team includes the folowing people: Mr. Christopher J. Reading, Pres, CEO & Director (Age 55)Mr. Lawrance W. McAfee, Exec. VP, CFO & Director (Age 64)Mr. Glenn D. McDowell, Chief Operating Officer of West (Age 62)Mr. Graham Reeve M.B.A., P.T., Chief Operating Officer of East (Age 55)Mr. Jon C. Bates, VP & Corp. Controller Who are U.S. Physical Therapy's major shareholders? U.S. Physical Therapy's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.08%), Kayne Anderson Rudnick Investment Management LLC (10.22%), Neuberger Berman Group LLC (7.07%), Renaissance Technologies LLC (4.06%), Dimensional Fund Advisors LP (3.83%) and Riverbridge Partners LLC (3.15%). Company insiders that own U.S. Physical Therapy stock include Bernard A Harris Jr, Christopher J Reading, Clayton Trier, Edward L Kuntz, Glenn Mcdowell, Harry S Chapman, Jerald L Pullins, Kathleen A Gilmartin, Lawrance W Mcafee, Mark J Brookner and Regg E Swanson. View Institutional Ownership Trends for U.S. Physical Therapy. Which institutional investors are selling U.S. Physical Therapy stock? USPH stock was sold by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Renaissance Technologies LLC, Riverbridge Partners LLC, Wellington Management Group LLP, AlphaOne Investment Services LLC, JPMorgan Chase & Co., Royce & Associates LP and First Trust Advisors LP. Company insiders that have sold U.S. Physical Therapy company stock in the last year include Christopher J Reading, Clayton Trier, Glenn Mcdowell, Jerald L Pullins, Lawrance W Mcafee and Mark J Brookner. View Insider Buying and Selling for U.S. Physical Therapy. Which institutional investors are buying U.S. Physical Therapy stock? USPH stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Neuberger Berman Group LLC, Hsbc Holdings PLC, Oxford Asset Management LLP, Virginia Retirement Systems ET AL, Geode Capital Management LLC, Cadence Capital Management LLC and Copeland Capital Management LLC. Company insiders that have bought U.S. Physical Therapy stock in the last two years include Harry S Chapman, Kathleen A Gilmartin and Regg E Swanson. View Insider Buying and Selling for U.S. Physical Therapy. How do I buy shares of U.S. Physical Therapy? Shares of USPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is U.S. Physical Therapy's stock price today? One share of USPH stock can currently be purchased for approximately $118.01. How big of a company is U.S. Physical Therapy? U.S. Physical Therapy has a market capitalization of $1.51 billion and generates $453.91 million in revenue each year. The company earns $34.87 million in net income (profit) each year or $2.65 on an earnings per share basis. U.S. Physical Therapy employs 4,600 workers across the globe. What is U.S. Physical Therapy's official website? The official website for U.S. Physical Therapy is http://www.usph.com. How can I contact U.S. Physical Therapy? U.S. Physical Therapy's mailing address is 1300 WEST SAM HOUSTON PARKWAY SUITE 300, HOUSTON TX, 77042. The company can be reached via phone at 713-297-7000 or via email at [email protected] MarketBeat Community Rating for U.S. Physical Therapy (NYSE USPH)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 270 (Vote Underperform)Total Votes: 452MarketBeat's community ratings are surveys of what our community members think about U.S. Physical Therapy and other stocks. Vote "Outperform" if you believe USPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: The Role of a Fiduciary and Individual Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.